## ENGROSSED SENATE BILL 5673

State of Washington 64th Legislature 2015 Regular Session

By Senators Padden, Kohl-Welles, Roach, Miloscia, Pearson, and Darneille

Read first time 01/28/15. Referred to Committee on Law & Justice.

- 1 AN ACT Relating to the distribution of synthetic cannabinoids and
- 2 bath salts; amending RCW 69.50.204 and 69.50.430; adding a new
- 3 section to chapter 19.86 RCW; creating a new section; and prescribing
- 4 penalties.
- 5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
- 6 <u>NEW SECTION.</u> **Sec. 1.** A new section is added to chapter 19.86 7 RCW to read as follows:
- 8 (1) It is a violation of RCW 19.86.020 for any person or entity
- 9 to distribute, dispense, manufacture, display for sale, offer for
- 10 sale, attempt to sell, or sell to a purchaser any product that
- 11 contains any amount of any synthetic cannabinoid, cathinone, or
- methcathinone as identified in RCW 69.50.204(e) (3) and (5).
- 13 (2) "Synthetic cannabinoid" includes any chemical compound
- 14 identified in RCW 69.50.204(c)(30) or by the pharmacy quality
- 15 assurance commission under RCW 69.50.201.
- 16 **Sec. 2.** RCW 69.50.204 and 2010 c 177 s 2 are each amended to
- 17 read as follows:
- 18 Unless specifically excepted by state or federal law or
- 19 regulation or more specifically included in another schedule, the
- 20 following controlled substances are listed in Schedule I:

p. 1 ESB 5673

```
1
             Any of the following opiates, including their isomers,
    esters, ethers, salts, and salts of isomers, esters, and ethers
 2
    whenever the existence of these isomers, esters, ethers, and salts is
 3
    possible within the specific chemical designation:
 4
 5
         (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-
 6
    piperidinyl]-N-phenylacetamide);
7
         (2) Acetylmethadol;
        (3) Allylprodine;
 8
        (4) Alphacetylmethadol, except levo-alphacetylmethadol,
9
    known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
10
11
        (5) Alphameprodine;
12
        (6) Alphamethadol;
                 Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)
13
        (7)
14
    ethyl-4-piperidyl] propionanilide); (1-(1-methyl-2-phenylethyl)-4-(N-
    propanilido) piperidine);
15
         (8) Alpha-methylthiofentanyl
16
                                         (N-[1-methyl-2-(2-thienyl)ethyl-4-
17
    piperidinyl]-N-phenylpropanamide);
        (9) Benzethidine;
18
19
        (10) Betacetylmethadol;
20
         (11)
                 Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
21
    piperidinyl]-N-phenylpropanamide);
         (12) Beta-hydroxy-3-methylfentanyl, some trade or other names: N-
22
23
    [1-(2-hydrox-2-phenethyl)-3-methyl-4-piperidinyl]-N-
    phenylpropanamide;
24
25
        (13) Betameprodine;
26
        (14) Betamethadol;
27
        (15) Betaprodine;
28
        (16) Clonitazene;
29
        (17) Dextromoramide;
30
        (18) Diampromide;
31
        (19) Diethylthiambutene;
32
        (20) Difenoxin;
33
        (21) Dimenoxadol;
        (22) Dimepheptanol;
34
        (23) Dimethylthiambutene;
35
36
        (24) Dioxaphetyl butyrate;
        (25) Dipipanone;
37
         (26) Ethylmethylthiambutene;
38
39
         (27) Etonitazene;
40
         (28) Etoxeridine;
```

p. 2 ESB 5673

```
1
         (29) Furethidine;
 2
        (30) Hydroxypethidine;
        (31) Ketobemidone;
 3
 4
         (32) Levomoramide;
 5
         (33) Levophenacylmorphan;
 6
         (34)
                   3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
7
    piperidyl]-N-phenylprop anamide);
                3-Methylthiofentanyl
                                       (N-[(3-methyl-1-(2-thienyl)ethyl-4-
 8
         (35)
9
    piperidinyl]-N-phenylpropanamide);
         (36) Morpheridine;
10
11
         (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
12
         (38) Noracymethadol;
        (39) Norlevorphanol;
13
14
        (40) Normethadone;
15
        (41) Norpipanone;
16
                    Para-fluorofentanyl
                                          (N-(4-fluorophenyl)-N-[1-(2-
17
    phenethyl)-4-piperidinyl] propanamide);
18
         (43) PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
19
         (44) Phenadoxone;
        (45) Phenampromide;
20
21
         (46) Phenomorphan;
22
        (47) Phenoperidine;
23
        (48) Piritramide;
        (49) Proheptazine;
24
25
        (50) Properidine;
26
        (51) Propiram;
27
         (52) Racemoramide;
28
         (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
29
    propanaminde);
30
        (54) Tilidine;
31
         (55) Trimeperidine.
32
         (b) Opium derivatives. Unless specifically excepted or unless
    listed in another schedule, any of the following opium derivatives,
33
    including their salts, isomers, and salts of isomers whenever the
34
    existence of those salts, isomers, and salts of isomers is possible
35
36
    within the specific chemical designation:
         (1) Acetorphine;
37
38
         (2) Acetyldihydrocodeine;
39
        (3) Benzylmorphine;
40
         (4) Codeine methylbromide;
```

p. 3 ESB 5673

```
1
        (5) Codeine-N-Oxide;
 2
        (6) Cyprenorphine;
 3
        (7) Desomorphine;
        (8) Dihydromorphine;
 4
        (9) Drotebanol;
 5
 6
         (10) Etorphine, except hydrochloride salt;
 7
        (11) Heroin;
        (12) Hydromorphinol;
 8
        (13) Methyldesorphine;
9
        (14) Methyldihydromorphine;
10
11
         (15) Morphine methylbromide;
12
         (16) Morphine methylsulfonate;
        (17) Morphine-N-Oxide;
13
14
        (18) Myrophine;
        (19) Nicocodeine;
15
16
        (20) Nicomorphine;
17
        (21) Normorphine;
        (22) Pholcodine;
18
        (23) Thebacon.
19
         (c) Hallucinogenic substances. Unless specifically excepted or
20
    unless listed in another schedule, any material, compound, mixture,
21
22
         preparation which contains any quantity of the
                                                                  following
    hallucinogenic substances, including their salts, isomers, and salts
23
    of isomers whenever the existence of those salts, isomers, and salts
24
25
    of isomers is possible within the specific chemical designation. For
26
    the purposes of this subsection only, the term "isomer" includes the
27
    optical, position, and geometric isomers:
28
              Alpha-ethyltryptamine:
                                        Some
                                               trade
                                                       or
                                                            other
                                                                     names:
29
    Etryptamine; monase; a-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)
    indole; a-ET; and AET;
30
31
         (2) 4-bromo-2,5-dimethoxy-amphetamine: Some trade or other names:
32
    4-bromo-2,5-dimethoxy-a-methylphenethylamine; 4-bromo-2,5-DMA;
             4-bromo-2,5-dimethoxyphenethylamine: Some trade or
33
    names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl
34
35
    DOB; 2C-B, nexus;
36
         (4) 2,5-dimethoxyamphetamine: Some trade or other names:
    dimethoxy-a-methylphenethylamine; 2,5-DMA;
37
```

(5) 2,5-dimethoxy-4-ethylamphetamine (DOET);

2,5-dimethoxy-4-(n)-propylthiophenethylamine:

38

39

40

2C-T-7;

p. 4 ESB 5673

Other

name:

```
1
        (7) 4-methoxyamphetamine: Some trade or other names: 4-methoxy-a-
 2
    methylphenethylamine; paramethoxyamphetamine, PMA;
        (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
 3
             4-methyl-2,5-dimethoxy-amphetamine: Some trade and other
 4
 5
             4-methyl-2,5-dimethoxy-a-methylphenethylamine;
    names:
                                                               "DOM";
                                                                       and
 6
     "STP";
7
        (10) 3,4-methylenedioxy amphetamine;
        (11) 3,4-methylenedioxymethamphetamine (MDMA);
8
9
        (12) 3,4-methylenedioxy-N-ethylamphetamine, also known
                                                                        N-
    ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine,
10
                                                            N-ethyl
                                                                      MDA,
11
    MDE, MDEA;
12
               N-hydroxy-3,4-methylenedioxyamphetamine
        (13)
                                                         also
                                                                known
                                                                        as
13
    N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine,N-hydroxy
14
    MDA;
        (14) 3,4,5-trimethoxy amphetamine;
15
16
        (15) Alpha-methyltryptamine: Other name: AMT;
17
               Bufotenine:
                             Some trade
        (16)
                                            or
                                                 other
                                                        names:
                                                                 3-(beta-
18
    Dimethylaminoethyl)-5-hydroxindole;
                                               3-(2-dimethylaminoethyl)-5-
19
              N, N-dimethylserotonin; 5-hydroxy-N, N-dimethyltryptamine;
    indolol;
20
    mappine;
21
        (17)
               Diethyltryptamine:
                                   Some
                                          trade
                                                  or
                                                      other
                                                                      N, N-
                                                              names:
22
    Diethyltryptamine; DET;
        (18) Dimethyltryptamine: Some trade or other names: DMT;
24
        (19) 5-methoxy-N, N-diisopropyltryptamine: Other name: 5-MeO-DIPT;
25
        (20) Ibogaine: Some trade or other names: 7-Ethyl-6,6 beta,
```

- 23

- 26 7,8,9,10,12,13,-octahydro-2-methoxy-6,9-methano-5H-pyndo (1',2'
- 27 azepino (5,4-b) indole; Tabernanthe iboga;
- 28 (21) Lysergic acid diethylamide;
- 29 (22) Marihuana or marijuana;
- (23) Mescaline; 30
- 31 (24) Parahexyl-7374: Some trade or other names: 3-Hexyl-1-
- 32 8, 9, 10-tetrahydro-6, hydroxy-7, 6, 9-trimethyl-6H-
- 33 dibenzo[b,d]pyran; synhexyl;
- (25) Peyote, meaning all parts of the plant presently classified 34
- botanically as Lophophora Williamsii Lemaire, whether growing or not, 35
- 36 the seeds thereof, any extract from any part of such plant, and every
- compound, manufacture, salts, derivative, mixture, or preparation of 37
- 38 such plant, its seeds, or extracts; (interprets 21 U.S.C. Sec. 812
- 39 (c), Schedule I (c)(12));
- 40 (26) N-ethyl-3-piperidyl benzilate;

p. 5 ESB 5673

- 1 (27) N-methyl-3-piperidyl benzilate;
- (28) Psilocybin; 2
- (29) Psilocyn; 3

14

19

- (30) Tetrahydrocannabinols, meaning tetrahydrocannabinols 4 naturally contained in a plant of the genus Cannabis (cannabis 5 6 plant), as well as synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, species, 7 and/or synthetic substances, derivatives, and their isomers with 8 similar chemical structure and pharmacological activity such as the 9
- following: 10 (i) 1 - cis - or trans tetrahydrocannabinol, and their optical 11 12 isomers, excluding tetrahydrocannabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by 13 the United States Food and Drug Administration;
- (ii) 6 cis or trans tetrahydrocannabinol, and their optical 15 16 isomers;
- 17 (iii) 3,4 - cis - or trans tetrahydrocannabinol, and its optical 18 isomers; or
  - (iv) That is chemically synthesized and either:
- (a) Has been demonstrated to have binding activity at one or more 20 21 cannabinoid receptors; or
- 22 (b) Is a chemical analog or isomer of a compound that has been demonstrated to have binding activity at one or more cannabinoid 23 24 receptors;
- 25 (Since nomenclature of these substances is not internationally 26 standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.) 27
- 28 (31) Ethylamine analog of phencyclidine: Some trade or other 29 N-ethyl-1phenylcyclohexalymine, (1-phenylcyclohex1) ethylamine; N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; PCE; 30
- 31 (32) Pyrrolidine analog of phencyclidine: Some trade or other 32 names: 1-(1-phencyclohexyl)pyrrolidine; PCPy; PHP;
- 33 (33) Thiophene analog of phencyclidine: Some trade or other 1-(1-[2-thenyl]-cyclohexly)-pipendine; 2-thienylanalog 34 phencyclidine; TPCP; TCP; 35
- 36 (34) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine: A trade or other 37 name is TCPy.
- (d) Depressants. Unless specifically excepted or unless listed in 38 39 another schedule, any material, compound, mixture, or preparation 40 which contains any quantity of the following substances having a

ESB 5673 p. 6

- 1 depressant effect on the central nervous system, including its salts,
- 2 isomers, and salts of isomers whenever the existence of such salts,
- 3 isomers, and salts of isomers is possible within the specific
- 4 chemical designation.
- 5 (1) Gamma-hydroxybutyric acid: Some other names include GHB;
- 6 gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid;
- 7 sodium oxybate; sodium oxybutyrate;
- 8 (2) Mecloqualone;
- 9 (3) Methagualone.
- 10 (e) Stimulants. Unless specifically excepted or unless listed in
- 11 another schedule, any material, compound, mixture, or preparation
- 12 which contains any quantity of the following substances having a
- 13 stimulant effect on the central nervous system, including its salts,
- 14 isomers, and salts of isomers:
- 15 (1) Aminorex: Some other names: aminoxaphen; 2-amino-5-phenyl-2-
- oxazoline; or 4, 5-dihydro-5-phenly-2-oxazolamine;
- 17 (2) N-Benzylpiperazine: Some other names: BZP,1-benzylpiperazine;
- 18 (3) Cathinone, also known as 2-amino-1-phenyl-1-propanone,
- 19 alpha-aminopropiophenone, 2-aminopropiophenone and norephedrone;
- 20 (4) Fenethylline;
- 21 (5) Methcathinone: Some other names: 2-(methylamino)-
- 22 propiophenone; alpha-(methylamino)propiophenone; 2-(methylamino)-1-
- 23 phenylpropan-1-one; alpha-N-methylaminopropiophenone;
- 24 monomethylpropion; ephedrone; N-methylcathinone; methylcathinone;
- 25 AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and
- 26 salts of optical isomers;
- 27 (6) (+-)cis-4-methylaminorex ((+-)cis-4,5-dihydro-4-methyl-5-
- 28 phenyl-2-oxazolamine);
- 29 (7) N-ethylamphetamine;
- 30 (8) N,N-dimethylamphetamine: Some trade or other names: N,N-
- 31 alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenoethylene.
- The controlled substances in this section may be added,
- 33 rescheduled, or deleted as provided for in RCW 69.50.201.
- 34 Sec. 3. RCW 69.50.430 and 2003 c 53 s 345 are each amended to
- 35 read as follows:
- 36 (1) Every person convicted of a felony violation of RCW 69.50.401
- 37 through 69.50.4013, 69.50.4015, 69.50.402, 69.50.403, 69.50.406,
- 38 69.50.407, 69.50.410, or 69.50.415 shall be fined one thousand
- 39 dollars in addition to any other fine or penalty imposed. Unless the

p. 7 ESB 5673

court finds the person to be indigent, this additional fine shall not be suspended or deferred by the court.

1

2

3

4

5

7

31

32

3334

35

36

3738

39

- (2) On a second or subsequent conviction for violation of any of the laws listed in subsection (1) of this section, the person shall be fined two thousand dollars in addition to any other fine or penalty imposed. Unless the court finds the person to be indigent, this additional fine shall not be suspended or deferred by the court.
- (3) In addition to any other civil or criminal penalty, every 8 person who violates or causes another to violate RCW 69.50.401 by 9 distributing, dispensing, manufacturing, displaying for sale, 10 offering for sale, attempting to sell, or selling to a purchaser any 11 product that contains any amount of any synthetic cannabinoid, 12 cathinone, or methcathinone, as identified in RCW 69.50.204, shall be 13 fined not less than ten thousand dollars and not more than five 14 hundred thousand dollars. If, however, the person who violates or 15 causes another to violate RCW 69.50.401 by distributing, dispensing, 16 17 manufacturing, displaying for sale, offering for sale, attempting to sell, or selling any product that contains any amount of any 18 synthetic cannabinoid, cathinone, or methcathinone, as identified in 19 RCW 69.50.204, to a purchaser under the age of eighteen, the minimum 20 21 penalty shall be twenty-five thousand dollars if the person is at least two years older than the minor. Unless the court finds the 22 person to be indigent, this additional fine shall not be suspended or 23 deferred by the court. 24
- NEW SECTION. Sec. 4. (1) The Washington state patrol shall create a pilot program that uses technologies and protocols to instantly identify synthetic cannabinoids, cathinones, and methcathinones (synthetic drugs), as well as other illicit drugs. The pilot program shall focus on using technology capable of presumptive identification of illicit drugs in the field.
  - (2) A minimum of five separate districts in the state shall be equipped to operate the pilot program. The state patrol may choose to have one or more of the pilot sites located within a city or county police department.
  - (3) Prior to July 30, 2016, the state patrol shall submit a report to the appropriate committees of the legislature outlining the findings of the pilot program, and make any recommendation on whether the technologies and protocols selected for the pilot program may be used to help prevent the growth of synthetic drugs and other illicit

p. 8 ESB 5673

drugs throughout the state. Specifically, the evaluation shall include, but is not limited to, the following:

1

2

3

4

5 6

7

8

9

- (a) A review of technical capabilities and accuracy rates of technologies and protocols selected for the pilot program;
- (b) A description of the impact to state and local crime lab backlogs if the technologies and protocols selected could eliminate the need to send synthetic drugs, or other illicit drugs, to the crime lab for presumptive testing, including the potential cost savings to state and local governments;
- 10 (c) A description of the status of courts' acceptance of the 11 technologies and protocols selected for the pilot program for the 12 presumptive identification of synthetic drugs and other illicit 13 drugs.

--- END ---

p. 9 ESB 5673